专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08481580B2 Lisofylline analogs and methods for use 有权
公开(公告)号：US08481580B2
公开(公告)日：2013-07-09
申请号：US12036646
申请日：2008-02-25
申请人： Timothy L. Macdonald , Jerry L. Nadler , Peng Cui
发明人： Timothy L. Macdonald , Jerry L. Nadler , Peng Cui
IPC分类号： A61P9/10 , A61P19/02 , A61P25/28 , A61K31/41 , C07D249/12
CPC分类号： A61K31/538 , A61K31/404 , A61K31/405 , A61K31/4196 , A61K31/495 , A61K31/502 , A61K31/53 , C07C215/68 , C07C219/32 , C07D209/08 , C07D209/80 , C07D221/08 , C07D223/22 , C07D241/08 , C07D241/18 , C07D249/12 , C07D253/04 , C07D265/26 , C07D265/36 , C07D265/38 , C07D275/04 , C07D279/22 , C07D487/04
摘要： The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.

2. 发明申请

US20130137693A1 LISOFYLLINE ANALOGS AND METHODS FOR USE 有权
标题翻译： LISOFYLLINE模拟和使用方法
公开(公告)号：US20130137693A1
公开(公告)日：2013-05-30
申请号：US13477613
申请日：2012-05-22
申请人： Timothy L. MACDONALD , Jerry L. NADLER , Peng CUI
发明人： Timothy L. MACDONALD , Jerry L. NADLER , Peng CUI
IPC分类号： C07D237/32
CPC分类号： A61K31/502 , C07D237/32
摘要： Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells.
摘要翻译：提供了莱索菲线（LSF）的类似物，以及制备此类类似物的合成方法。所提供的LSF的类似物具有保护细胞活力的能力，特别是保护胰腺β细胞的能力。

3. 发明申请

US20090269313A1 ENCAPSULATION SYSTEM 审中-公开
标题翻译：封装系统
公开(公告)号：US20090269313A1
公开(公告)日：2009-10-29
申请号：US12373870
申请日：2007-07-19
申请人： Jerry L. Nadler
发明人： Jerry L. Nadler
IPC分类号： A61K35/12 , A61P3/10
CPC分类号： A61K35/39
摘要： An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula: wherein: X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S; R1 is selected from a member of the group consisting of hydrogen, methyl, C(5-9)alkyl, C(5-9)alkenyl, C(5-9)alkynyl, C(5-9)hydroxyalkyl, C(3-8)alkoxyl, C(5-9)alkoxyalkyl, the R1 being optionally substituted; R2 and R3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：提供了一种用于治疗糖尿病的包封系统（1型或2型和LADA型）。该系统具有（1）包含选择性渗透膜的输送载体，其允许葡萄糖，胰岛素和其它营养物通过膜，但是阻止大分子例如抗体或炎性细胞通过膜; （2）由所述膜包封的胰岛细胞群体或产生胰岛素的细胞群; 和（3）可以与膜接触或被膜包封的生物反应调节剂。通常，生物反应调节剂是具有下列结构式的拆分的对映异构体，非对映异构体，互变异构体，盐和溶剂化物的化合物：其中：X，Y和Z独立地选自C（R3），N，N（R3）和S; R 1选自氢，甲基，C（5-9）烷基，C（5-9）烯基，C（5-9）炔基，C（5-9）羟基烷基，C（3） -8）烷氧基，C（5-9）烷氧基烷基，R1任选被取代; R 2和R 3独立地选自氢，卤素，氧代，C（1-20）烷基，C（1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧基烯基，C（1-20）氨基烷氧基炔基，C（1-20）二氨基烷基，C（1-20） C 1-20 1-20烷基氨基烷基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）乙酰氨基烷基，C（1-20） 1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基和C（1-20）二烷氧基烷基。

4. 发明授权

US06486181B1 Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states 失效
标题翻译：人类白细胞12-脂肪氧合酶及其在疾病发病机理中的作用
公开(公告)号：US06486181B1
公开(公告)日：2002-11-26
申请号：US09691845
申请日：2000-10-18
申请人： Jerry L. Nadler , Rama Natarajan
发明人： Jerry L. Nadler , Rama Natarajan
IPC分类号： A61K3144
CPC分类号： A61K31/00 , A61K31/045 , A61K31/05 , A61K31/155 , A61K31/195 , A61K31/20 , A61K31/35 , A61K31/352 , A61K31/44 , A61K31/4439 , A61K31/575 , C12N9/0069 , C12N15/113 , C12Q1/26 , C12Y113/11012 , C12Y113/11031 , G01N33/573 , G01N33/6893 , G01N2333/90241 , G01N2800/042
摘要： The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics.
摘要翻译：本发明涉及一种抑制患有由过量的12-脂肪氧合酶或其产物引起的疾病状态的患者的疾病病因的方法。特别地，本发明提供了用于抑制疾病病因的人白细胞12-脂肪氧合酶途径抑制剂，抑制乳腺癌的增殖并增加患有II型糖尿病患者的胰岛素受体磷酸化。

5. 发明授权

US06485976B1 Use of adeno-associated virus (AAV) to deliver genes 有权
标题翻译：使用腺相关病毒（AAV）传递基因
公开(公告)号：US06485976B1
公开(公告)日：2002-11-26
申请号：US09559915
申请日：2000-04-28
申请人： Jerry L. Nadler , David Bleich , Konkal-Matt R. Prasad
发明人： Jerry L. Nadler , David Bleich , Konkal-Matt R. Prasad
IPC分类号： C12N1563
CPC分类号： C12N15/86 , A61K38/44 , A61K48/00 , C12N2750/14143
摘要： This invention pertains to a method of protecting pancreatic &bgr;-cells from immune system-mediated cell damage through transduction of the cells with an adeno-associated viral vector encoding cytoprotective genes. These protected cells are suitable for transplantation into mammals and will be protected from rejection by the host. The method also may be used to protect pancreatic islet &bgr;-cells in situ for the primary prevention of immune-mediated destruction which leads to Type 1 diabetes. Pancreatic &bgr;-cells may be transduced with AAV vectors according to the invention for in vivo or ex vivo gene therapy.
摘要翻译：本发明涉及通过用编码细胞保护基因的腺相关病毒载体转导细胞来保护胰腺β-细胞免受免疫系统介导的细胞损伤的方法。这些受保护的细胞适合于移植到哺乳动物中，并且将被保护免受宿主的排斥。该方法还可用于原位保护胰岛β细胞，以初步预防免疫介导的破坏，导致1型糖尿病。胰腺β细胞可以用根据本发明的用于体内或体外基因治疗的AAV载体转导。

6. 发明授权

US06191169B1 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states 失效
标题翻译：人类白细胞12-脂肪氧合酶及其在疾病发病机理中的作用
公开(公告)号：US06191169B1
公开(公告)日：2001-02-20
申请号：US08945744
申请日：1997-11-03
申请人： Jerry L. Nadler , Rama Natarajan
发明人： Jerry L. Nadler , Rama Natarajan
IPC分类号： A61K31195
CPC分类号： A61K31/045 , A61K31/00 , A61K31/05 , A61K31/155 , A61K31/195 , A61K31/20 , A61K31/35 , A61K31/352 , A61K31/44 , A61K31/4439 , A61K31/575 , C12N9/0069 , C12N15/113 , C12Q1/26 , C12Y113/11012 , C12Y113/11031 , G01N33/573 , G01N33/6893 , G01N2333/90241 , G01N2800/042 , Y10S514/866
摘要： The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics.
摘要翻译：本发明涉及一种抑制患有由过量的12-脂肪氧合酶或其产物引起的疾病状态的患者的疾病病因的方法。特别地，本发明提供了用于抑制疾病病因的人白细胞12-脂肪氧合酶途径抑制剂，抑制乳腺癌的增殖并增加患有II型糖尿病患者的胰岛素受体磷酸化。

7. 发明申请

US20130096159A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE 审中-公开
标题翻译：人类12-LIPOXYGENASE的抑制剂
公开(公告)号：US20130096159A1
公开(公告)日：2013-04-18
申请号：US13698340
申请日：2011-05-18
申请人： David J. Maloney , Theodore Holman , Ajit Jadhav , Anton Simeonov , Ganesha Rai Bantukallu , Jerry L. Nadler , Michael Holinstat
发明人： David J. Maloney , Theodore Holman , Ajit Jadhav , Anton Simeonov , Ganesha Rai Bantukallu , Jerry L. Nadler , Michael Holinstat
IPC分类号： C07D409/04 , C07D215/28
CPC分类号： C07D409/04 , C07D215/28 , C07D215/38 , C07D405/06 , C07D409/06
摘要： Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.
摘要翻译：公开了式（I）或（II）的人类12-脂肪氧合酶抑制剂，其中R1，R2，R3和R4如本文所定义，其可用于治疗或预防12-脂肪氧合酶介导的疾病或病症，糖尿病。还公开了包含药学上可接受的载体和本发明的至少一种抑制剂的组合物，以及治疗或预防哺乳动物中的这种疾病或病症的方法。

8. 发明申请

US20100331248A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE AND ISLET NEOGENESIS ASSOCIATED PEPTIDE 审中-公开
标题翻译：使用LISOFYLLINE和ISLET NEOGENESIS相关肽治疗糖尿病的组合物和方法
公开(公告)号：US20100331248A1
公开(公告)日：2010-12-30
申请号：US12865027
申请日：2009-02-02
申请人： Mary Ann Latona Nadler , Jerry L. Nadler
发明人： Mary Ann Latona Nadler , Jerry L. Nadler
IPC分类号： A61K38/22 , A61K31/522 , A61P3/10
CPC分类号： A61K38/10 , A61K31/502 , A61K31/522 , A61K31/5377 , A61K31/695 , A61K38/1709 , A61K2300/00
摘要： Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline (LSF) is an immunomodulator that reduces cytokine signaling and reduces the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of LSF and INGAP after pre-treatment with LSF is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.
摘要翻译：提供药物组合物和方法用于治疗有需要的哺乳动物的糖尿病和/或恢复和/或细胞质量和功能。 1型糖尿病（T1DM）是以胰腺β细胞免疫损伤为特征的自身免疫性疾病。赖索阵列（LSF）是一种免疫调节剂，可减少细胞因子信号并减少非肥胖型糖尿病（NOD）小鼠T1DM的发生。与LSF（预处理）和INGAP联合治疗可以保护免受自身免疫破坏。 LSF预处理后的LSF和INGAP的伴随或组合对于由哺乳动物胰岛细胞或胰岛素产生的损失导致的疾病或病症是有效的治疗方法。

9. 发明授权

US06693106B2 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) 有权
标题翻译：己酮可可碱，吡格列酮和二甲双胍是形成晚期糖基化终末产物（AGE）的抑制剂
公开(公告)号：US06693106B2
公开(公告)日：2004-02-17
申请号：US10096579
申请日：2002-03-14
申请人： Samuel Rahbar , Jerry L. Nadler
发明人： Samuel Rahbar , Jerry L. Nadler
IPC分类号： A61K31522
CPC分类号： A61K31/196 , A61K31/155 , A61K31/198 , A61K31/4439 , A61K31/522 , A61K31/606
摘要： Pentoxifylline, pioglitazone and metformin have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become perturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, atherosclerosis and spoilage of proteins in food and can prevent discoloration of teeth.
摘要翻译：已经发现己酮可可碱，吡格列酮和二甲双胍抑制蛋白质的非酶糖基化，这通常导致晚期糖基化终产物和交联的形成。蛋白质的非酶糖基化和交联是衰老过程的一部分，其中长寿命蛋白质的糖基化终产物和交联随年龄增长。在血液中和细胞内环境中还原糖浓度升高时，如糖尿病发生，该过程增加。受影响的分子的结构和功能完整性受到这些修饰的干扰，并可能导致严重后果。本发明的化合物可用于抑制非酶糖基化的方法，并因此抑制由糖尿病或老化引起的一些不良作用。该化合物还可用于预防过早衰老，类风湿性关节炎，阿尔茨海默病，尿毒症，神经毒性，动脉粥样硬化和食物中蛋白质的变质，并可防止牙齿变色。

10. 发明申请

US20110052625A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE 审中-公开
标题翻译：用类似的方法治疗糖尿病的组合物和方法和血小板生成相关肽
公开(公告)号：US20110052625A1
公开(公告)日：2011-03-03
申请号：US12865062
申请日：2009-02-02
申请人： Mary Ann Latona Nadler , Jerry L. Nadler
发明人： Mary Ann Latona Nadler , Jerry L. Nadler
IPC分类号： A61K38/10 , A61P3/10
CPC分类号： A61K38/10 , A61K31/502 , A61K31/522 , A61K31/5377 , A61K31/695 , A61K38/1709 , A61K2300/00
摘要： Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.
摘要翻译：提供药物组合物和方法用于治疗有需要的哺乳动物的糖尿病和/或恢复和/或细胞质量和功能。 1型糖尿病（T1DM）是以胰腺β细胞免疫损伤为特征的自身免疫性疾病。赖索丝线类似物（LSF类似物）是免疫调节剂，其减少非肥胖性糖尿病（NOD）小鼠中的IL-12信号并减少T1DM的发生。使用LSF类似物（预处理）和INGAP的联合治疗可以防止自身免疫破坏。与LSF类似物预处理后的LSF类似物和INGAP的伴随或组合是由哺乳动物胰岛细胞或胰岛素产生丧失导致的疾病或病症的有效治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式